Evidence map›Paper›PMID 36245434›Full record

ArticleHepatology communications2022

Clinical and demographic predictors of survival for fibrolamellar carcinoma patients-A patient community, registry-based study.

Amichai Berkovitz, Rachael D Migler, Adam Qureshi, Carly Rosemore, Michael S Torbenson, Roger Vaughan, Erin Marcotte, Sanford M Simon

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Amichai BerkovitzLaboratory of Cellular Biophysics, The Rockefeller University, New York, New York, USA.
Rachael D MiglerThe Fibrolamellar Registry, New York, New York, USA.
Adam QureshiHospital Biostatistics, The Rockefeller University, New York, New York, USA.
Carly RosemoreLaboratory of Cellular Biophysics, The Rockefeller University, New York, New York, USA.
Michael S TorbensonDivision of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Roger VaughanHospital Biostatistics, The Rockefeller University, New York, New York, USA.
Erin MarcotteDepartment of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA.
Sanford M SimonLaboratory of Cellular Biophysics, The Rockefeller University, New York, New York, USA.ORCID 0000-0002-8615-4224
Fibrolamellar Cancer Foundation · USRockefeller University Hospital · USMayo Clinic · USMemorial Sloan Kettering Cancer Center · USRockefeller University · USUniversity of Minnesota · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Project 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI Zongming Eric Chen · 2018 to 2026
$20.5M
What differences between the chimeric fusion oncoprotein DNAJB1-PRKACA and native kinase PRKACA lead to transformation in the childhood cancer, fibrolamellar hepatocellular carcinoma?U54CA243126 · NCI · ROCKEFELLER UNIVERSITY · PI SIMON, SANFORD M · 2019 to 2023
$5.4M
NCATS NIH HHS UL1 TR001866NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA210964NCI NIH HHS U54 CA243126
6 · The paper itself

Abstract

Fibrolamellar hepatocellular carcinoma (FLC) is a rare primary liver cancer that affects primarily adolescents and young adults. It is associated with a poor overall prognosis. There is a need to better define risk factors, but small sample size has limited such studies. An FLC patient registry now provides data sufficient for statistically robust inferences. We leveraged a unique patient community-based FLC registry to analyze the prognostic impact of demographic and clinical characteristics evident at diagnosis. Variables were analyzed using Cox proportional hazards regression to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). In multivariable models of 149 patients (88 females and 61 males), female gender was associated with statistically significant improved survival with HR of 0.52 (95% CI 0.29-0.93). Factors evident at diagnosis that are associated with worse survival included the presence of 10 or more tumors within the liver (HR 7.1; 95% CI 2.4-21.04), and metastases at diagnosis (HR 2.17; 95% CI 1.19-3.94). Positive lymph nodes at diagnosis, despite being found significantly associated with worse survival in a univariate analysis, did not remain significant when adjusted for covariates in a multivariable analysis. We found no statistically significant effect of age at diagnosis nor tumor size at diagnosis on survival. Female gender may confer a favorable prognosis in FLC. Established high-risk prognostic factors that we confirmed in this Registry included the diagnostic presence of numerous intrahepatic tumors, and metastases. This is the first study derived from a FLC patient community-based registry, and highlights how registries of rare tumors can empower patients to meaningfully advance clinical and scientific discoveries.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAdolescentDemographyFemaleHumansMaleRegistriesYoung Adult

Identifiers

PMID36245434
PMCPMC9701473
OpenAlexW4306399303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.